Protagonist Therapeutics
PTGX
PTGX
92 hedge funds and large institutions have $728M invested in Protagonist Therapeutics in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.82% more ownership
Funds ownership: 99.47% → 101.29% (+1.8%)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
86% less call options, than puts
Call options by funds: $1K | Put options by funds: $7K
Holders
92
Holding in Top 10
2
Calls
$1K
Puts
$7K
Top Buyers
| 1 | +$46.3M | |
| 2 | +$15.1M | |
| 3 | +$8.1M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.27M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$4.89M |
Top Sellers
| 1 | -$6.79M | |
| 2 | -$6.16M | |
| 3 | -$6.02M | |
| 4 |
D.E. Shaw & Co
New York
|
-$5.57M |
| 5 |
Renaissance Technologies
New York
|
-$3.82M |